Screener / SEC EDGAR /CIK 0001104506 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

INSMED Inc INSM

Compare with peers Embed
What it said it expected, against what it reported

1 target with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 0 of 1 range targets
Below the range 0 below the last range given

The numbers INSM said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given at least $1.00B release Feb 19, 2026
Kept at least $1.00B release May 7, 2026
Changed $1.25B to $1.40B release Aug 6, 2026
– Not reported yet
The company's words
Insmed anticipates full-year 2026 BRINSUPRI revenues of at least $1 billion. release Feb 19, 2026
The Company continues to anticipate full-year 2026 BRINSUPRI revenues of at least $1 billion. release May 7, 2026
The Company raised its guidance for full-year 2026 BRINSUPRI revenues to a range of $1.25 billion to $1.40 billion from the previous guidance of release Aug 6, 2026
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $340.00M to $360.00M release Feb 22, 2024
Kept $340.00M to $360.00M release May 9, 2024
Kept $340.00M to $360.00M release Aug 8, 2024
Kept $340.00M to $360.00M release Oct 31, 2024
$363.71M
10-K filed 2025-02-20
Above the range
The company's words
Insmed is reiterating its sales guidance for full-year 2024 global … ARIKAYCE revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release Feb 22, 2024
Insmed is reiterating its sales guidance for full-year 2024 global … ARIKAYCE revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release May 9, 2024
Insmed is reiterating its guidance for full-year 2024 global ARIKAYCE … revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release Aug 8, 2024
Insmed is reiterating its guidance for full-year 2024 global ARIKAYCE … revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release Oct 31, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-22), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSM/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.